201 related articles for article (PubMed ID: 25667618)
1. Efficacy of
Öztürk H; Karapolat I
Exp Ther Med; 2015 Mar; 9(3):717-724. PubMed ID: 25667618
[TBL] [Abstract][Full Text] [Related]
2. Role of
Ozturk H
Rep Pract Oncol Radiother; 2023; 28(6):728-736. PubMed ID: 38515818
[TBL] [Abstract][Full Text] [Related]
3. Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography.
Öztürk H
Cancer Res Treat; 2015 Oct; 47(4):834-43. PubMed ID: 25687863
[TBL] [Abstract][Full Text] [Related]
4.
Öztürk H; Karapolat I
Oncol Lett; 2016 Jan; 11(1):316-322. PubMed ID: 26870210
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma.
Ozturk H
Minerva Urol Nefrol; 2016 Jun; 68(3):263-9. PubMed ID: 25916217
[TBL] [Abstract][Full Text] [Related]
7. Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers.
Harkirat S; Anand S; Jacob M
Indian J Radiol Imaging; 2010 Feb; 20(1):13-9. PubMed ID: 20351986
[TBL] [Abstract][Full Text] [Related]
8. Added Clinical Value of
van Ginkel N; van Gennep EJ; Oosterbaan L; Greidanus J; Boellaard TN; Wondergem M; Vis AN; de Reijke TM; van Rhijn BWG; Mertens LS
Clin Genitourin Cancer; 2023 Jun; 21(3):342-348. PubMed ID: 36918302
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
10. Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer.
Al-Zubaidi M; Ong K; Viswambaram P; Bangash H; Boardman G; McCombie SP; Oey O; Swarbrick N; Redfern A; Ong J; Gauci R; Low R; Hayne D
BJUI Compass; 2024 Apr; 5(4):473-479. PubMed ID: 38633828
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
12. [(18)F]Fluorodeoxyglucose - positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy.
Kollberg P; Almquist H; Bläckberg M; Cronberg C; Garpered S; Gudjonsson S; Kleist J; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2015; 49(4):296-301. PubMed ID: 25623843
[TBL] [Abstract][Full Text] [Related]
13. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
Uttam M; Pravin N; Anish B; Nandita K; Arup M
Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
[TBL] [Abstract][Full Text] [Related]
14. Pelvic Lymph Node Staging by Combined
Pichler R; De Zordo T; Fritz J; Kroiss A; Aigner F; Heidegger I; Virgolini I; Horninger W; Uprimny C
Clin Genitourin Cancer; 2017 Jun; 15(3):e387-e395. PubMed ID: 27601364
[TBL] [Abstract][Full Text] [Related]
15. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
Fitoussi O; Roche JB; Riviere J; Wallerand H; Poulain JE; Gordien P; Galland S; Henriques B; Dupin C; Vincent M; Kuratle T; Saffarini M; Ramos-Pascual S
Urol Int; 2023; 107(3):239-245. PubMed ID: 36657430
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
18. Role of fluorodeoxyglucose positron emission tomography/computed tomography in diagnostic evaluation of carcinoma urinary bladder: comparison with computed tomography.
Chakraborty D; Mittal BR; Kashyap R; Mete UK; Narang V; Das A; Bhattacharya A; Khandelwal N; Mandal AK
World J Nucl Med; 2014 Jan; 13(1):34-9. PubMed ID: 25191110
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of
Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection.
Sun L; Guan YS; Pan WM; Luo ZM; Wei JH; Zhao L; Wu H
World J Gastrointest Oncol; 2009 Oct; 1(1):55-61. PubMed ID: 21160775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
